A study published in 2024 (126) demonstrated that DPP-4 inhibitors showed potential benefits in patients with type 1 myotonic dystrophy (DM1), including a reduction in blood glucose levels in some patients, improvement of insulin secretion, and preservation of insulin secretory capacity. The gene discussed is DPP4; the disease is myotonic dystrophy type 1.